Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epirubicin + pemetrexed
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of epirubicin (an anthracycline topoisomerase II inhibitor) and pemetrexed (a multi-targeted antifolate). This combination has been investigated for the treatment of locally advanced or metastatic breast cancer. While the regimen demonstrated safety, it showed limited efficacy in phase II studies with only 23% of patients achieving partial response, below the predefined efficacy requirements.
02
Targets
TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on epirubicin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epirubicin + pemetrexed.